The tRNA-derived fragment 5026a inhibits the proliferation of gastric cancer cells by regulating the PTEN/PI3K/AKT signaling pathway

Linwen Zhu1,2,3, Zhe Li1,2, Xiuchong Yu2, Yao Ruan2, Yijing Shen2, Yongfu Shao1,4, Xinjun Zhang1,4, Guoliang Ye1,4 and Junming Guo1,2,4*

Abstract

Background: Recently, tRNA-derived fragments (tRFs) have been shown to serve important biological functions. However, the role of tRFs in gastric cancer has not been fully elucidated. This study aimed to identify the tumor suppressor role of tRF-5026a (tRF-18-79MP9P04) in gastric cancer.

Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was first used to detect tRF-5026a expression levels in gastric cancer tissues and patient plasma. Next, the relationship between tRF-5026a levels and clinicopathological features in gastric cancer patients was assessed. Cell lines with varying tRF-5026a levels were assessed by measuring tRF-5026a using qRT-PCR. After transfecting cell lines with a tRF-5026a mimic or inhibitor, cell proliferation, colony formation, migration, apoptosis, and cell cycle were evaluated. The expression levels of related proteins in the PTEN/PI3K/AKT pathway were also analyzed by Western blotting. Finally, the effect of tRF-5026a on tumor growth was tested using subcutaneous tumor models in nude mice.

Results: tRF-5026a was downregulated in gastric cancer patient tissues and plasma samples. tRF-5026a levels were closely related to tumor size, had a certain diagnostic value, and could be used to predict overall survival. tRF-5026a was also downregulated in gastric cancer cell lines. tRF-5026a inhibited the proliferation, migration, and cell cycle progression of gastric cancer cells by regulating the PTEN/PI3K/AKT signaling pathway. Animal experiments showed that upregulation of tRF-5026a effectively inhibited tumor growth.

Conclusions: tRF-5026a (tRF-18-79MP9P04) is a promising biomarker for gastric cancer diagnostics and has tumor suppressor effects mediated through the PTEN/PI3K/AKT signaling pathway.

Keywords: tRNA-derived small RNAs, tRF-5026a, tRF-18-79MP9P04, Gastric cancer, PTEN, PI3K

* Correspondence: guojunming@nbu.edu.cn
1Department of Gastroenterology, The Affiliated Hospital of Ningbo University School of Medicine, Ningbo 315020, China
2Department of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo 315211, China
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Gastric cancer is one of the most common digestive tract tumors worldwide [1]. Early-stage gastric cancer patients do not typically experience discomfort or any symptoms. Consequently, most gastric cancer patients are diagnosed with middle- and late-stage disease, resulting in a 5-year postoperative survival rate of as low as 25%. However, the 5-year postoperative survival rate for early-stage gastric cancer is 90–95% [2]. Therefore, it is vitally important to study the molecular mechanisms underlying gastric cancer occurrence to help identify biomarkers for the early detection of gastric cancer.

Noncoding RNAs (ncRNAs) are a class of RNAs that do not encode proteins. ncRNA mutations or abnormal expression are closely related to the development of many diseases. MicroRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) have been demonstrated to play a role in the occurrence, development, and prognosis of gastric cancer [3–7].

Recently, tRNA-derived small RNAs (tsRNAs), which were once mistaken for random tRNA degradation products, have been found to have important biological functions [8]. These small ncRNAs are produced by specific cleavage of precursor tRNAs or mature tRNAs at different sites [8–10]. These tsRNAs act as signaling molecules in stress responses and regulate gene expression [11, 12]. Therefore, there is potential for the broad application of tsRNAs in disease diagnosis and treatment. tsRNAs mainly include tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) [13–16]. tRFs are approximately 14–31 nucleotides (nt) in length and can be further classified based on their source: tRF-1, tRF-2, tRF-3, tRF-5, and i-tRF [13]. tiRNAs can also be divided into two subclasses: 5′-tiRNA and 3′-tiRNA [13].

High-throughput sequencing and database screening have revealed disease-associated tsRNAs [17–19]. In this study, we screened tRF-5026a through tRFdb (http://genome.bioch.virginia.edu/trfdb/) [14] and MINTbase (1D: tRF-18-79MP9P04; https://cm.jefferson.edu/MINTbase/) [17], which indicated that tRF-5026a (tRF-18-79MP9P04) is a gastric cancer-associated tRF. However, its diagnostic value and biological roles in gastric cancer are unclear. tRF-5026a, belonging to the tRF-5 subgroup, comes from mature tRNA-Val−AAC and tRNA-Val−CAC. We found that tRF-5026a had value in the diagnosis of gastric cancer. Furthermore, by upregulating and downregulating the expression of tRF-5026a in gastric cancer cells, we found that tRF-5026a regulated the growth of gastric cancer cells through the PTEN/P13K/AKT signaling pathway. These results helped to increase our understanding of gastric cancer and suggested that tRF-5026a may be useful as a biomarker and therapeutic target of gastric cancer.

Materials and methods
Tissue and plasma samples
In this study, 86 pairs of gastric cancer tissues and their corresponding adjacent nontumor tissues were collected at the Affiliated People’s Hospital of Ningbo University, China. Nontumor tissues located 5 cm away from the edge of cancerous tissue were visually confirmed to have no obvious tumor cells. Tissue specimens were immediately preserved in RNAlater Reagent (Biotek, Beijing, China) after removal from the patient and kept at –80 °C until further use. In addition, fasting plasma samples were collected from 37 gastric cancer patients 1 day before and 7 days after surgery. Fresh normal plasma samples were collected from 37 healthy age- and sex-matched normal donors at Ningbo No. 1 Hospital. Ethylenediaminetetraacetic acid (EDTA) was used as the anticoagulant in the tubes used for blood collection.

All tissue samples included in this study were pathologically diagnosed. All clinical data were collected by experienced physicians. The researchers were blinded to the clinical data when operating.

Cell culture and transfection
The normal gastric mucosal epithelial cell line GES-1 was purchased from the Chinese Academy of Medical Sciences Cancer Hospital (Beijing, China). The gastric cancer cell lines AGS, MGC-803, HGC-27, BGC-823, and SGC-7901 were purchased from the Shanghai Institute of Life Sciences, Chinese Academy of Sciences (Shanghai, China). AGS cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (HyClone, Logan, UT, USA) supplemented with 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA) and 10% fetal bovine serum (FBS) (PAN-Biotech, Aidenbach, Germany) at 5% CO2 and 37 °C. The gastric cancer cell lines MGC-803, HGC-27, BGC-823, and SGC-7901 and the normal gastric mucosal epithelial cell line GES-1 were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (HyClone, Logan, UT, USA) supplemented with 10% FBS and 1% penicillin/streptomycin at 5% CO2 and 37 °C.

Cells were seeded in cell culture plates or culture flasks. When the cells reached 40–60% confluency, the cells were transfected with 0.5 μM tRF-5026a mimic or inhibitor with Lipofectamine 2000 transfection reagent (Life Technologies, Carlsbad, CA, USA). The sequences of the tRF-5026a mimic and inhibitor negative control were 5′-GUUUCGGUAGUGUGG-3’ and 5′-UUGUACUACAAAGAUGUCUG-3′, respectively. The sequences of the tRF-5026a inhibitor and inhibitor negative control were 5′-CCACUAUCUACGAAAC-3′ and 5′-CAGUACUUUGUGUAGUACAA-3′, respectively. The oligos were designed and synthesized by Genepharma Co., Ltd. (Shanghai, China).
**Total RNA extraction**

Total RNA in tissues and cells was extracted with TRIzol reagent, while RNA was extracted from plasma with TRIzol LS reagent (Invitrogen, Karlsruhe, Germany). The RNA quality was then measured using a SmartSpec Plus Ultra-Micro Spectrophotometer (Bio-Rad, Hercules, CA, USA). The RNA purity was assessed based on the A260/A280 values [19], where values of 1.8–2.1 were considered acceptable. RNA was stored at −80 °C until further use.

**RNA pretreatment and reverse transcription**

The length of tRF-5026a is 18 nt and is therefore too short to detect with quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Adaptors were utilized to mitigate this problem. However, RNA modifications that are typically observed with tRFs and tiRNAs, such as 3′-aminoacyl, methylation, and 2′,3′-cyclic phosphate, were of concern [19]. These modifications can block the end binding of adaptors to the RNA terminus, where internal methylation can hinder cDNA synthesis during reverse transcription (RT). The rtStar™ tRF and tRNA Pretreatment Kit (Arraystar, Rockville, MD, USA) was used to remove these modifications. The 3′ adaptor contained a universal RT primer (5′-AGAT CGGACGCGG-3′). The 5′ adaptor and 3′ adaptor sequences used were 5′-TCGGCCGACGATC-3′ and 5′-CCGCGTGCGATCT-3′, respectively. The manufacturer’s protocol was followed for RNA pretreatment (demodification) [19]. The rtStar™ First-Strand cDNA Synthesis Kit (Arraystar) was then used to synthesize cDNA for the detection of tRFs with qRT-PCR.

**PCR analysis**

Upon adding cDNA, the PCR mix was assembled with GoTaq qPCR Master Mix (Promega, Madison, WI, USA) according to the manufacturer’s protocol. PCR was performed on an Mx3005P Real-Time PCR machine (Stratagene, Palo Alto, CA, USA). Small nuclear RNA RNU6-2 was used as an external reference control for tRF-5026a. The ΔCq method was used to analyze the expression levels, where a lower ΔCq value indicates a higher expression. The relative expression was calculated using the 2−ΔΔCq method. Data are expressed as the mean ± standard deviation (SD) of experiments conducted in triplicate. The primer sequences for qRT-PCR are shown in Supplementary Table S1. Sequencing was performed by Thermo Fisher Scientific. In addition, we measured the tRF-5026a levels with Northern blotting by designing a specific complementary probe sequence (5′-CCACTACACTACGGAAAC-3′).

**Cell proliferation assay**

Cell proliferation was assayed with a Cell Counting Kit 8 (CCK-8) (Dojindo Molecular Technologies, Kumamoto, Japan). Specifically, 24 h after transfection with the tRF-5026a mimic or inhibitor, 5 × 10^3 cells in 100 μL were seeded per well of a 96-well plate. Each treatment was performed with six replicates. After incubating the cells in a CO₂ incubator for 24 h, a total of 10 μL of CCK-8 solution was added to each well, and the cells were incubated for an additional 3 h. Finally, the absorbance was measured at 450 nm with a microplate reader (SpectraMax M5, Molecular Devices, CA, USA).

**Colony formation assay**

tRF-5026a mimic- or inhibitor-transfected cells were added to a 6-well plate (500 cells/well) 24 h post transfection and cultured in a CO₂ incubator. Each condition was performed in triplicate. After culturing the cells for 15 days, the cells were gently rinsed with phosphate-buffered saline (PBS) once or twice and then fixed with 1 mL/well of a 4% paraformaldehyde solution for 30 min. The cells were stained with 1 mL of 0.1% crystal violet dye for 30 min, and the plate was rinsed gently with tap water several times. After drying, a picture was taken and used for analysis.

**Cell migration assay**

A Transwell assay was used to measure cell migration. Transfected cells were first incubated in a CO₂ incubator for 24 h and then resuspended in Opti-MEM I Reduced-Serum Medium (Gibco). A total of 8 × 10^4 cells (200 μL) were added to the upper chamber of a Transwell insert (Costar, Corning, NY, USA), and 500 μL of RPMI 1640 medium containing 10% FBS was added to the lower chamber. After the cells were cultured at 37 °C in a CO₂ incubator for 24 h, the cells were fixed and stained with paraformaldehyde fixation and crystal violet dye. The migrating cells were then counted.

**Cell cycle detection**

The cells were first starved for one day in serum-free medium to synchronize the cell cycles. After transfection, the cells were collected in a flow tube. One milliliter of DNA staining solution and 10 μL of permeabilization solution (Multi Sciences) were added. After vortexing the tubes for 5–10 s, the cells were incubated for 30 min in the dark at room temperature. Finally, the stained cells were run on a FACSCalibur Flow
Cytometer (BD Biosciences). The data were analyzed with Modifit software (BD Biosciences).

**Western blot analysis**

The cells were first lysed with radioimmunoprecipitation assay lysis buffer (Solarbio, Beijing, China). The protein levels were then quantified using a Bradford assay kit (Beyotime, Haimen, China). After the protein samples were separated by 12% SDS-polyacrylamide gel electrophoresis, the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). The membranes were blocked and incubated with primary antibodies, followed by washing with Tris-buffered saline and Tween 20 (TBST). Secondary antibodies were then incubated with the membranes followed by washing with TBST. Finally, the proteins were detected using WesternBright ECL HRP (Advansta, Menlo Park, CA, USA) and the signals were detected with a Clinx GenoSens 1600 integrated gel imaging analysis system (Clinx, Shanghai, China). The primary antibodies that were directed against phosphates and tensin homolog deleted on chromosome ten gene (PTEN), phosphatidylinositide 3-kinase 3-kinase B (PI3K), and protein kinase B (AKT), as well as the goat anti-mouse IgG and goat anti-rabbit IgG secondary antibodies, were all purchased from Cell Signaling Technology Company (Danvers, MA, USA).

**Subcutaneous tumor model**

Male 3-week-old BALB/c nude mice purchased from the Shanghai Siliake Laboratory Animal Center (Siliake, Shanghai, China) were housed in a specific pathogen-free environment in the Experimental Animal Center of Ningbo University, China. After consulting the literature, we found that gastric cancer SGC-7901 and MGC-803 cells have good tumorigenic properties [20, 21]. Therefore, the SGC-823 and MGC-803 cells were used for xenograft studies. The mice were split into the following groups: mimic negative control, low concentration mimic (0.05 μM), and high concentration mimic (0.1 μM). Each group contained six mice each. A total of 5 × 10⁶ cells in 150 μL were injected subcutaneously. Treatments were given every other week. After tumor formation, the tumor volumes were measured every other day, and the mice were sacrificed 1 month later. After the tumors were removed, their sizes and masses were measured. The major organs were also assessed macroscopically for changes.

**Statistical analysis**

The data were expressed as the mean ± SD and were analyzed using Statistical Program for Social Sciences (SPSS) 20.0 (IBM, Chicago, IL, USA) software. Differences between groups were evaluated using a two-sided Student’s t-test. P < 0.05 was considered meaningful.

**Results**

**Low expression of tRF-5026a is observed in gastric cancer tissues and cells**

To detect tRF-5026a levels by qRT-PCR, specific amplification primers for tRF-5026a were designed that spanned both the tRF-5026a and adaptor sequences. Agarose gel electrophoresis showed that the qRT-PCR product length was consistent with its theoretical length (44 bp) (Fig. 1a). To further confirm the qRT-PCR product was correct, T-A cloning and sequencing were performed. The alignment results (Fig. 1b) were consistent with the base sequence of tRF-5026a obtained from the MINTbase database (https://cm.jefferson.edu/MINTbase/) and the tRFdb database (http://genome.bioch.virginia.edu/trdfb/search.php), indicating that the primers for tRF-5026a were capable of specifically amplifying tRF-5026a.

To understand the expression of tRF-5026a in gastric cancer, 86 pairs of gastric cancer and adjacent tissues were collected. tRF-5026a was expressed at low levels in gastric cancer tissues, as assessed by qRT-PCR (Fig. 1c). We also measured the expression of tRF-5026a in gastric cancer and paracancerous tissues using Northern blotting. Northern blotting confirmed that tRF-5026a was indeed expressed at low levels in gastric cancer tissues and that the length of tRF-5026a (18 nt) and its mature tRNA (76 nt) were consistent with the theoretical length (Fig. 1d). From the qRT-PCR data, we observed that 79.1% (68/86) of the samples expressed low amounts of tRF-5026a (Fig. 1e).

Plasma is one of the most commonly collected sample types in the clinic. We therefore measured plasma tRF-5026a levels in gastric cancer patients and healthy controls. Healthy people had higher plasma tRF-5026a levels than gastric cancer patients both one day prior to and 7 days postoperatively (Fig. 1f). In addition, tRF-5026a plasma levels of postoperative patients were higher than those of preoperative patients (Fig. 1f); that is, after the tumor was removed by surgery, the plasma tRF-5026a level tended to increase to the level of healthy people.

To further investigate tRF-5026a expression in gastric cancer, we explored the expression levels of tRF-5026a at the cellular level. tRF-5026a was expressed at lower levels in gastric cancer cells (AGS, MGC-803, HGC-27, BGC-823, and SGC-7901) than in normal gastric mucosal epithelial cells (GES-1), as assessed by qRT-PCR (Fig. 1g). These cell line data were consistent with the data from the tissue and plasma samples (Fig. 1e, f).

**Diagnostic value of tRF-5026a in gastric cancer**

Given that the levels of tRF-5026a were different in malignant tissues, plasma samples, and cell lines compared...
to normal conditions (Fig. 1), tRF-5026a therefore has the potential to serve as a biomarker of gastric cancer. To assess this potential, we first analyzed the area under the receiver operating characteristic (ROC) curve (AUC) of tRF-5026a and then measured the relationship between tRF-5026a expression levels in gastric cancer tissues and the clinicopathological features of gastric cancer patients. Using the postoperative follow-up data of gastric cancer patients, survival curves were drawn to evaluate the outcomes of the gastric cancer patients. Finally, independent predictors of gastric cancer prognosis were identified by single factor and multivariate Cox regression analysis.

For tissue expression of tRF-5026a, the AUC was 0.631, and the sensitivity and specificity were 0.512 and 0.721, respectively, for a cutoff value of 14.03 (Fig. 2a). For plasma expression of tRF-5026a, the AUC was 0.883, and the sensitivity and specificity were 0.973 and 0.676, respectively, for a cutoff value of 8.81 (Fig. 2a). The diagnostic efficiency of tRF-5026a as a biomarker was significantly improved when using a combination of tissue and plasma expression data. The combined AUC was 0.908, with a sensitivity and specificity of 0.946 and 0.811, respectively (Fig. 2a).

The combined use of several biomarkers is a useful method to improve their diagnostic value [22]. We previously found that tiRNA-5034-GluTTC-2 could be a potential biomarker of gastric cancer [19]. We combined the tRF-5026a and tiRNA-5034-GluTTC-2 data to determine whether the diagnostic value increased. When we combined the tissue and plasma levels of both tRF-5026a and tiRNA-5034-GluTTC-2, the AUC increased to 0.938, with a sensitivity of 0.919 and a specificity of 0.865 (Fig. 2b).

In addition, after analyzing the clinicopathological features of gastric cancer patients, we found that tRF-5026a expression levels were associated with tumor serum marker carbohydrate antigen 19-9 (CA19-9) levels (P = 0.026) and tumor size (P = 0.001) (Supplementary Table S3). A survival curve analysis found that tRF-5026a expression levels in tissues from gastric cancer patients correlated with overall survival (OS), where the OS of the low tRF-
5026a expression group was shorter than that of the high expression group (Fig. 2c). Univariate and multivariate analyses showed that tRF-5026a was associated with TNM stage and lymph node metastasis and was a good independent prognostic biomarker for gastric cancer (Supplementary Table S4).

**Effects of tRF-5026a on cell proliferation**

To study the role of tRF-5026a in gastric cancer, we used a tRF-5026a mimic and inhibitor to modulate the expression levels in gastric cancer cells. The tRF-5026a levels were upregulated by the tRF-5026a mimic in a normal gastric mucosal epithelial cell line (GES-1) and gastric cancer cell lines (AGS, MGC-803, HGC-27, BGC-823, and SGC-7901), as measured by qRT-PCR (Supplementary Fig. S1a). We also successfully downregulated tRF-5026a expression in the normal gastric mucosal epithelial cell line GES-1 and the gastric cancer cell lines AGS, HGC-27, BGC-823, and SGC-7901 (Supplementary Fig. S1b).

The CCK-8 assay revealed that in the normal gastric mucosal epithelial cell line GES-1 (Supplementary Fig. S2a, b) and the gastric cancer cells AGS (Supplementary Fig. S2c, d), BGC-823 (Supplementary Fig. S2e, f), and SGC-7901 (Supplementary Fig. S2 g, h), increasing tRF-5026a levels inhibited proliferation, while decreasing tRF-5026a promoted proliferation.

We further verified the suppressive effects of tRF-5026a on the proliferative capacity by using a colony formation assay. In the normal gastric mucosal epithelial cell line GES-1 and the gastric cancer cell lines AGS, BGC-823, and SGC-7901, the tRF-5026a mimic decreased colony formation, while the inhibitor increased colony formation (Fig. 3).

**Effects of tRF-5026a on cell migration**

The effects of tRF-5026a levels on cell migration were analyzed using a Transwell assay. The migratory capabilities of the normal gastric mucosal epithelial cell line GES-1 and the gastric cancer cell lines AGS, BGC-823, and SGC-7901 were decreased with the tRF-5026a mimic and increased by the inhibitor (Supplementary Fig. S3).
Effects of tRF-5026a on proliferation in gastric cancer (Supplementary Fig. S2, Fig. 3), we next measured the effects of tRF-5026a on the cell cycle. Increasing tRF-5026a levels resulted in a G0/G1 block in the normal gastric mucosal epithelial cell line GES-1 and the gastric cancer cell lines AGS, BGC-823, and SGC-7901, as measured by flow cytometry (Fig. 4). Interestingly, decreasing tRF-5026a levels caused a block at G2/M in these cell lines. These findings indicated that tRF-5026a regulated cell cycle progression.

Effects of tRF-5026a on the expression of signal transduction-related proteins
To further investigate the effects of tRF-5026a on proliferation, migration, and cell cycle (Figs. 3 and 4), we next examined whether tRF-5026a was involved in the PTEN/PI3K/AKT signaling pathway because this pathway is a fundamental player in biological activities such as cell proliferation, migration, and the cell cycle [23, 24]. PI3K and AKT are positive regulators, while PTEN is a negative regulator of this pathway.

We selected the poorly differentiated gastric cancer cell line BGC-823 and the moderately differentiated gastric cancer cell line SGC-7901 as representative gastric cancer cell lines to study the effects of tRF-5026a on the expression of PTEN, PI3K, and AKT. We found that increasing tRF-5026a levels in gastric cancer cells resulted in a decrease in PI3K and AKT levels, with an increase in PTEN levels (Fig. 5). Conversely, decreasing tRF-5026a levels resulted in an increase in PI3K and AKT levels and a decrease in PTEN levels (Fig. 5).
Effects of tRF-5026a on the growth of transplanted tumors in animal models

To further elucidate the role of tRF-5026a in gastric cancer, we performed a subcutaneous tumor formation experiment in nude mice. Increasing tRF-5026a levels in the gastric cancer cell lines SGC-7901 (Fig. 6a, b) and MGC-803 (Fig. 6c, d) significantly inhibited the tumor growth rate as measured by the tumor volume (Fig. 6e, g) and tumor weight changes (Fig. 6f, h) in a dose-dependent manner compared with the control group. Moreover, tumor growth in the gastric cancer cell line MGC-803 was completely prevented in 5/6 mice in the high concentration tRF-5026a mimetic group (Fig. 6c, d). The possible reasons are as follows: (1) The baseline level of tRF-5026a in MGC-803 cells was lower than that in SGC-7901 cells (Fig. 1g); and (2) the upregulation effects of the tRF-5026a mimic on the level of tRF-5026a between MGC-803 cells and SGC-7901 cells were not significantly different (Fig. S1). These results indicate that MGC-803 cells are more sensitive to the tRF-5026a mimic than SGC-7901 cells.

Although there were no significant differences between the baseline levels of tRF-5026a in GES-1 and SGC-7901 cells (Fig. 1g), we did not use the GES-1 cells in the animal experiment because it is a normal gastric mucosal epithelial cell line and does not form xenografts.

Discussion

The main role of tRNAs is to carry amino acids to the ribosome, thereby facilitating the synthesis of the corresponding protein under the guidance of the mRNA. In recent years, it has been found that many tsRNAs (tRFs and tiRNAs) produced under specific conditions are in fact not random tRNA degradation products [25]. Moreover, many studies have recently shown that tRFs and tiRNAs can be found in a variety of cancers [26–29]. tRFs and tiRNAs can affect the development of cancer by regulating transcription, altering mRNA stability, inhibiting translation, and regulating ribosome biogenesis [15]. tRFs and tiRNAs can also affect cancer development by regulating cell proliferation, metastasis, apoptosis, and the cell cycle [30, 31]. These tsRNAs can influence the expression levels of endogenous target genes [25, 32, 33]. Some tRFs and tiRNAs also form complexes with Ago and Piwi, indicating that these tRFs and tiRNAs can function as miRNAs or piRNAs [26]. tRFs and tiRNAs also serve as regulators of gene expression and the stress response [34].

The rich modifications observed on tRFs and tiRNAs [8, 9] increase their stability in tissues, plasma, and cells compared with other ncRNAs (e.g., lncRNAs, circRNAs, and miRNAs) [35–37]. In addition, tRFs and tiRNAs are highly enriched in plasma samples and other bodily
fluids [38, 39]. Pretreatment of total RNAs and the addition of an adaptor prior to qRT-PCR results in higher yields and lower dimer production rates when trying to measure the levels of these tsRNAs [40]. In addition, tRFs and tiRNAs are abnormally expressed in cancer and can be detected efficiently. tRFs and tiRNAs are therefore prospective new biomarkers for the noninvasive diagnosis of gastric cancer.

Studies have found that tsRNAs are differently expressed in stem cells who are in different differentiation states and affect their genes’ transcription and translation [41]. Huang et al. found that tRF/miR-1280 can promote cancer stem cells (CSCs) in the progression of colorectal cancer [28]. Many tsRNAs were detected in embryonic stem cells (ESCs) and induced pluripotent stem cells [42]. Guzzi et al. found that in mammalian stem cells, post-transcriptional RNA modification affected the biogenesis and function of tRFs [43]. PTEN/PI3K/Akt pathway is related to CSCs in various cancers [44–46]. Dubrovska et al. found that the PTEN/PI3K/Akt pathway was closely related to prostate CSCs and PI3K might be an effective therapeutic target of prostate cancer [45]. In non-small cell lung cancer (NSCLC), PI3K/AKT pathway plays a great role in the enrichment of CSCs, thereby promoting the occurrence and development of NSCLC [46]. And some small RNAs such as miR-873 inhibits the proliferation and differentiation of pancreatic CSCs mediated through PI3K/AKT signaling pathway [47]. Here, we found that tRF-5026a inhibited the occurrence and development of gastric cancer through PI3K/AKT signaling pathway.

This study mainly aimed to screen for and identify gastric cancer-related tRFs and to explore their biological functions. tRFs have the potential to play a major role in gastric cancer diagnostics because tRFs are more stable than traditional ncRNAs, and many ncRNAs have demonstrated potential utility in gastric cancer diagnostics. It remains to be determined how tRFs regulate the occurrence and development of gastric cancer.

In this study, we measured representative gastric cancer-associated tRFs at three levels, the cellular, animal, and clinical levels, and studied their possible biological functions. We found that tRF-5026a was downregulated in gastric cancer tissues, plasma samples and cells (Fig. 1), indicating that tRF-5026a may have a tumor suppressor role and can be used as a potential biomarker for gastric cancer diagnosis (Fig. 2). We found that increasing tRF-5026a levels inhibited cell proliferation and migration and arrested the cell cycle process, whereas silencing tRF-5026a resulted in increased proliferation and migration (Figs. 3 and 4).

We then evaluated whether tRF-5026a could affect the development of gastric cancer by acting on critical signaling pathways. Because the PI3K/AKT signaling pathway is one of the fundamental pathways identified in the development of gastric cancer, we measured the effects of tRF-5026a on the expression of key proteins in this pathway. The PI3K/AKT signaling pathway plays a role...
in promoting cell proliferation, preventing cell apoptosis, and promoting cell viability [48]. PI3K and AKT are positive regulators of this pathway, while PTEN acts as a negative regulator of the PI3K/AKT signaling pathway. PI3K is dephosphorylated to phosphatidylinositol di-phosphate (PIP2) by using phosphatidylinositol triphosphate (PIP3) as a substrate. Because PIP3 is a product of PI3K that mediates the activation of AKT and dephosphorylation to PIP2 is accomplished under the action of PTEN, PTEN therefore inhibits the activity of the PI3K/AKT signaling pathway [49, 50]. We found that upregulating tRF-5026a levels inhibited the PI3K/AKT signaling pathway, while downregulating tRF-5026a promoted activation of the PI3K/AKT pathway (Fig. 5). These effects led to either inhibited cell proliferation and migration, arrested cell cycle progression, or increased proliferation and migration (Figs. 3 and 4). The PI3K/AKT signaling pathway, which is overactive in many cancers, regulates
the proliferation, migration, invasion, and cell cycle progression of cancer cells and is closely related to tumor neovascularization, endothelial growth, and replication potential [51]. Our study demonstrated that tRF-5026a inhibited the growth of gastric cancer cells by regulating the PI3K/AKT signaling pathway and it exerted a tumor suppressor effect (Fig. 5). However, one of the limits of this study is that the RNAs and proteins that directly bind to tRF-5026a were not identified, which needs to be addressed in future studies.

In conclusion, tRF-5026a (tRF-18-79MP9P04) is a potential biomarker for the diagnosis of gastric cancer. tRF-5026a (tRF-18-79MP9P04) had tumor suppressive effects in gastric cancer mediated through the PTEN/PI3K/AKT signaling pathway.

Abbreviations
AKT: Protein kinase B; AUC: Receiver operating characteristic curve; CA19-9: Carbohydrate antigen 19-9; CCK-8: Cell counting kit 8; circRNAs: Circular RNAs; DMEM: Dulbecco's modified Eagle's medium; EDTA: Ethylenediaminetetraacetic acid; FBS: Fetal bovine serum; fmiRNAs: tRNA halves; OS: Overall survival; PBS: Phosphate-buffered saline; lncRNAs: Long noncoding RNAs; miRNAs: MicroRNAs; ncRNAs: Noncoding RNAs; nt: Nucleotides; NT: Neutralization test; PIP2: Phosphatidylinositol diphosphate; PIP3: Phosphatidylinositol triphosphate; PTEN: Tensin homolog deleted on chromosome ten gene; PVDF: Polyvinylidene fluoride; qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; ROC: Receiver operating characteristic; RT: Reverse transcription; SD: Standard deviation; SPF: Specific reverse transcription-polymerase chain reaction; TiRNAs: tRNA halves; tRFs: tRNA-derived fragment; TRFs: tRNA-derived small RNAs.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13287-021-02497-1.

Additional file 1: Supplementary Table S1. Primer sequences for qRT-PCR.
Supplementary Table S2. Sensitivity, specificity, AUC of tRF-5026a expression in patients with gastric cancer tissues. Supplementary Table S3. The relationships between the expression levels of tRF-5026a (ΔCt) in tissues and the clinicopathological factors of patients with gastric cancer. Supplementary Table S4. Univariate and multivariate Cox regression analysis of the overall survival of tRF-5026a expression in patients with gastric cancer tissues. Supplementary Fig. S1. The use of tRF-5026a mimic and inhibitor to modulate its levels in normal gastric mucosal epithelial cells and gastric cancer cells. a The up-regulation effect of tRF-5026a mimic. b The down-regulation effect of tRF-5026a inhibitor. nc, negative control; n=3, * P<0.05, ** P<0.01, *** P<0.001. Supplementary Fig. S2. Effects of tRF-5026a on gastric cancer cell proliferation. a, b Grow curve of normal gastric mucosal epithelial cell line(GES-1) following up- and down-regulation by tRF-5026a mimic and inhibitor, respectively. c, h Grow curve of gastric cancer cell lines (AGS, BGC-823, SGC-7901) following up- and down-regulation by tRF-5026a mimic and inhibitor, respectively. nc, negative control; n=6, ** P<0.01, *** P<0.001. Supplementary Fig. S3. Effects of tRF-5026a on cell migration. a Transwell assay of tRF-5026a mimic and inhibitor of the normal gastric mucosal epithelial cell line (GES-1) and gastric cancer cell lines (AGS, BGC-823, SGC-7901). b Transwell assay of tRF-5026a inhibitor of the normal gastric mucosal epithelial cell line (GES-1) and gastric cancer cell lines (AGS, BGC-823, SGC-7901). Left, representative results. Right, data are presented as the mean ± SD, n=3, nc, negative control, * P<0.05, ** P<0.01, *** P<0.001.

Acknowledgements
The authors thank for the technical support by the Core Facilities, Ningbo University School of Medicine.

Authors’ contributions
J.G. conceived this project. L.Z. and J.G. designed the study. L.Z. performed most of the experiments and analyzed the data. L.Z. and Z.L. conducted the animal experiments. Y.Y., Y.R., and Y.S. provided essential advice. Y.S., Z.X., and G.Y. collected clinical samples. L.Z. and J.G. wrote the manuscript. The author(s) read and approved the final manuscript.

Funding
This study was supported by grants from the National Natural Science Foundation of China (no. 81974316). Zhejiang Provincial Natural Science Foundation of China (no. LGF21H000004), and the K.C. Wong Magna Fund in Ningbo University.

Availability of data and materials
The authors declare that the data supporting the findings of this study are available in the article and associated Supplementary Information. Extra data or information are available from the corresponding authors upon reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Human Research Ethics Committee at Ningbo University (approval number 2019022501) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients.

The animal experiments were reviewed and approved by The Animal Research Ethics Committee from Ningbo University before execution (approval number 2019-57).

Consent for publication
Not applicable.

Competing interests
The authors declare that there are no competing interests.

Author details
1Department of Gastroenterology, The Affiliated Hospital of Ningbo University School of Medicine, Ningbo 315020, China. 2Department of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo 315211, China. 3Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315041, China. 4Institute of Digestive Diseases of Ningbo University, Ningbo 310520, China.

Received: 28 December 2020 Accepted: 7 July 2021

Published online: 22 July 2021

References
1. Mo X, Wu Y, Chen L, Zhai M, Gao Z, Hu K, et al. Global expression profiling of metabolic pathway-related lncRNAs and their related protein-annotation of metabolism-associated lncRNAs and their related protein-encoding genes in gastric cancer. Mol Genet Genomic Med. 2018;6(5):729–38. https://doi.org/10.1002/mtg3.12472.
2. Liu X, Meltzer SJ. Gastric cancer in the era of precision medicine. Cell Mol Gastroenterol Hepatol. 2017;3(3):348–58. https://doi.org/10.1016/j.jcmgh.2017.02.003.
3. Wang Y, Li Z, Xu S, Guo J. Novel potential tumor biomarkers: circular RNAs and exosomal circular RNAs in gastrointestinal malignancies. J Clin Lab Anal. 2020;34(7):e23359. https://doi.org/10.1002/jcla.23359.
4. Tan B, Li Y, Di Y, Fan L, Zhao Q, Liu Q, et al. Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. J Clin Lab Anal. 2018;32(4):e22692. https://doi.org/10.1002/jcla.22692.
5. Mo X, Li T, Xie Y, Zhu L, Xiao B, Liao Q, et al. Identification and functional annotation of metabolism-associated lncRNAs and their related protein-encoding genes in gastric cancer. Mol Genet Genomic Med. 2018;6(5):729–38. https://doi.org/10.1002/mtg3.12472.
6. Xie Y, Shao Y, Sun W, Ye G, Zhang X, Xiao B, et al. Downregulated expression of hsa_circ_0074362 in gastric cancer and its potential diagnostic values. Biomark Med. 2018;12(1):11–20. https://doi.org/10.2217/ bmm-2017-0114.
7. Shao Y, Li J, Lu R, Li T, Yang Y, Xiao B, et al. Global circular RNA expression profile of human gastric cancer and its clinical significance. Cancer Med. 2017;6(6):1173–80. https://doi.org/10.1002/cam4.1055.

8. Xie Y, Yao L, Yu X, Ruan Y, Li Z, Guo J. Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduct Target Ther. 2020;5(1):109. https://doi.org/10.1038/s41392-020-00217-4.

9. Kumar P, Kuczko D, Dutta A. Biogenesis and function of transfer RNA-related fragments (tRFs). Trends Biochem Sci. 2016;41(8):679–89. https://doi.org/10.1016/j.tibs.2016.05.004.

10. Shen Y, Yu X, Zhu L, Li T, Yan Z, Guo J. Transfer RNA-derived fragments and tRNA halves: biogenensis, biological functions and their roles in diseases. J Mol Med (Berl). 2019;96(11):1167–76. https://doi.org/10.1007/s00109-018-1699-y.

11. Schimmel P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat Rev Mol Cell Biol. 2018;19(1):45–58. https://doi.org/10.1038/nrm.2017.77.

12. Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, et al. A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature. 2017;552(7683):57–62. https://doi.org/10.1038/nature23685.

13. Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: The new players in cancers. Cancer Lett. 2019;452:31–7. https://doi.org/10.1016/j.canlet.2019.03.012.

14. Kumar P, Mudunuri SB, Anaya J, Dutta A. tRFdb: a database for transfer RNA fragments. Nucleic Acids Res. 2015;43(Database issue):D141–5. https://doi.org/10.1093/nar/gku1338.

15. Li S, Xu Z, Shen Y. tRNA-derived small RNA: a novel regulatory small non-coding RNA Genes (Basel). 2018;9(5):246. https://doi.org/10.3390/genes9050246.

16. Kumar P, Anaya J, Mudunuri SB, Dutta A. Meta-analysis of tRNA-derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol. 2014;12(1):78. https://doi.org/10.1186/1471-2180-14-78.

17. Shen Y, Yu X, Ruan Y, Li Z, Xie Y, Yan Z, et al. Global profile of tRNA-derived small RNAs in gastric cancer patient plasma and identification of tRF-33-PHHRP1PON4VPD as a new tumor suppressor. Int J Med Sci. 2021;18(7):1570–9. https://doi.org/10.7150/ijms.53220.

18. Zhu L, Li T, Shen Y, Yu X, Xiao B, Guo J. Using tRNA halves as novel biomarkers for the diagnosis of gastric cancer. Cancer Biomark. 2019;25(2):169–76. https://doi.org/10.3233/CBM-182194.

19. Li K, Du H, Lian X, Chai D, Li X, Yang R, et al. Establishment and characterization of a metastasis model of human gastric cancer in nude mice. BMC Cancer. 2016;16(1):54. https://doi.org/10.1186/s12885-016-2101-z.

20. Mao W, Zhu X, Tang D, Zhao Y, Zhao B, Ma G, et al. tRF-expression in the UCB-MSCs as stable source inhibits gastric cancers growth in nude mice. Cancer Invest. 2012;30(6):643–72. https://doi.org/10.1080/07357900.2012.675385.

21. Li P, Chen H, Chen S, Mo X, Li T, Xiao B, et al. Circular RNA, 0000096 affects cell growth and migration in gastric cancer. Br J Cancer. 2017;116(5):626–33. https://doi.org/10.1038/bjc.2016.451.

22. Serbetçioğlu RM, Biedermann J, Lellouche G, Bresters V, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005;12(1):90–100. https://doi.org/10.1038/sj.cgt.7700775.

23. Rodrigues Alves A, Fernandes J, Fenerich B, Coelho-Silva J, Scheucher P, et al. tRNA fragments in mammalian development. RNA Biol. 2020;17(8):1214–23. https://doi.org/10.1080/15476286.2020.1732694.

24. Xi P, Xu X. PI3K/Akt/mTOR signaling pathway in cancer stem cells from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–12. https://doi.org/10.7150/ajcr.29744.

25. Zhu K, Kim S, Schageman J, Zeringer E, Li M, Barta T, Lea K, et al. Systematic analysis of tRNA-derived small RNAs reveals novel potential therapeutic targets of traditional Chinese Medicine (Bu-yang-Huan-wu-Decoration) on intracranial hemorrhage. Int J Biol Sci. 2019;15(4):895–908. https://doi.org/10.7150/ijbs.29744.

26. Maute RL, Schneider C, Sumazin P, Holmes A, Califano A, Basso K, et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in CB lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1404–9. https://doi.org/10.1073/pnas.1206761110.

27. Li S, Shi X, Chen M, Xu N, Sun D, Bai R, et al. Angiogenin promotes colorectal cancer metastasis via tRNA production. Int J Cancer. 2019;145(5):1395–407. https://doi.org/10.1002/ijc.32245.

28. Obreja A, Huvanagiri V. Small RNAs derived from the 3′ end of tRNA can inhibit protein translation in human cells. RNA Biol. 2013;10(4):553–63. https://doi.org/10.4161/mbio.24285.

29. Zheng LL, Xu XL, Liu S, Sun WJ, Li JH, Wu J, et al. tRF: a Cancer. A web server to detect tRNA-derived small RNA fragments (tRFs) and their expression in multiple cancers. Nucleic Acids Res. 2016;44(41):W185–93. https://doi.org/10.1093/nar/gkw414.

30. Schageman J, Zergering E, Li M, Barta T, Lea K, Gu J, et al. The complete exosome workflow solution: from isolation to characterization of tRNA cargo. Biomed Res Int. 2013;2013:259576.

31. Orai3-mediates cisplatin-resistance in non-small cell lung cancer cells by modulating the PI3K/AKT pathway. Cancers. 2019;11(1):268. https://doi.org/10.3390/cancers11010073.

32. Zhang H, Sun L, Liu Y, Wang H, Liu Z, Yang Y, et al. Diagnostic and prognostic signatures from the small non-coding RNA-Seq data: a vade mecum for MINTmap. Methods Mol Biol. 2018;1680:237–55.

33. Zheng H, Gao C, Yang H, Cheng X, Wang D, Fu S, Shen W, et al. PI3K/AKT/mTOR suppresses stem cell-like cells and metastasis in colorectal cancer. Cancer Res. 2017;77(12):3194–206. https://doi.org/10.1158/0008-5472.CAN-16-3146.

34. Martens-Uzunova ES, Jalaee S, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012;31(8):978–91. https://doi.org/10.1038/onc.2011.304.

35. Telonis AG, Loher P, Magee R, Platsika V, Londin E, Kirino Y, et al. tRNA fragments show intertwining with mRNAs of specific repeat content and have links to disparities. Cancer Res. 2019;79(12):3034–9. https://doi.org/10.1158/0008-5472.CAN-19-0789.

36. Sun C, Fu Z, Wang S, Li J, Li Y, Zhang Y, et al. Roles of tRNA-derived fragments in human cancers. Cancer Lett. 2019;414:16–25. https://doi.org/10.1016/j.canlet.2017.10.031.

37. Shao Y, Li J, Mudunuri SB, Dutta A. tRF: a database for transfer RNA fragments. Nucleic Acids Res. 2015;43(Database issue):D141–5. https://doi.org/10.1093/nar/gku1338.

38. Yang Q, Jiang W, Hou P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112–24. https://doi.org/10.1016/j.semcancer.2019.04.001.
49. Shen F, Zong ZH, Liu Y, Chen S, Sheng XJ, Zhao Y. CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signalling pathway. Biomed Pharmacother. 2019;114:108787. https://doi.org/10.1016/j.biopha.2019.108787.

50. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. https://doi.org/10.1186/s12943-019-0954-x.

51. Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res. 2019;38(1):112. https://doi.org/10.1186/s13046-019-1043-0.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.